Metastatic castration-resistant prostate cancer (mCRPC) is an incurable condition associated with poor prognosis and quality of life. Historically, patients with mCRPC had limited therapeutic options, and despite advancements in therapeutic innovation, the five-year relative survival rate for metastatic prostate cancer remains low (~34%). Encouragingly, multiple randomized clinical trials have recently demonstrated promising responses to novel poly (ADP-ribose) polymerase (PARP) inhibitors – such as talazoparib, niraparib and olaparib, in combination with androgen receptor pathway inhibitors – and represent a new class of therapies for first-line treatment of mCRPC.
However, there has been no direct comparative trial conducted between these combinations of PARP and androgen receptor pathway inhibitors. When such trial data is unavailable, indirect treatment comparisons (ITCs) may be used to estimate their relative efficacy.
To help aid clinical decision-making in treatment selection, the Value & Evidence team at EVERSANA (Imtiaz A. Samjoo, Anja Haltner, Samantha Craigie, Di Wang, Sarah Walsh) – along with Dr. Elena Castro and the team at Pfizer Inc. (Alexander Niyazov and Jonathan Nazari) – conducted a matching-adjusted indirect comparison (MAIC) between these combination therapies. This technique involves matching the treatment cohorts on eligibility criteria and reweighting the matched patients in one study to align with the characteristics of those in another.
This study highlights the importance of indirect comparative evidence in the absence of head-to-head randomized clinical trials in guiding optimal treatment strategies for patients living with mCRPC. For decision-makers and clinicians, our findings offer valuable insights into the relative efficacy of these first-line treatment options.
For a deeper understanding, access the full article in Prostate Cancer and Prostatic Diseases: https://www.nature.com/articles/s41391-024-00924-x.
Author
As Senior Director of the Value & Evidence team at EVERSANA, Imtiaz leads evidence synthesis projects that support global HEOR initiatives involving systematic literature reviews, indirect treatment comparisons, and health economic modeling, to support reimbursement…
Anja brings over 10 years of academic and industry experience in applied statistical analyses. Anja’s research focuses on population-adjusted indirect treatment comparisons including matching-adjusted indirect comparisons, simulated treatment comparisons, and propensity score matching and…
Samantha Craigie holds an MSc in Epidemiology and Biostatistics from the University of Western Ontario. As an Associate Director at EVERSANA in Evidence Synthesis, Samantha has led many global SLR and ITC projects for…
Di is a senior biostatistician on Value & Evidence team at EVERSANA, with extensive experience in conducting indirect treatment comparisons. Since joining EVRSANA in 2022, Di has been involved in the implementation of various…
Sarah is a Manager on the Value & Evidence team at EVERSANA and provides statistical support and guidance on evidence synthesis projects. Sarah brings over six years of academic experience and a strong background…